Rafael Holdings, Inc. (NYSE:RFL) Short Interest Update

Rafael Holdings, Inc. (NYSE:RFL) was the recipient of a significant decline in short interest in the month of January. As of January 30th, there was short interest totaling 53,017 shares, a decline of 14.3% from the January 15th total of 61,844 shares. Based on an average daily volume of 80,249 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.2% of the shares of the company are sold short. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 80,249 shares, the days-to-cover ratio is presently 0.7 days.

Hedge Funds Weigh In On Rafael

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock worth $1,897,000 after buying an additional 133,024 shares during the last quarter. Geode Capital Management LLC grew its position in Rafael by 72.9% in the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after acquiring an additional 190,179 shares during the last quarter. Cable Car Capital LP acquired a new position in Rafael during the second quarter worth about $173,000. Citadel Advisors LLC lifted its holdings in shares of Rafael by 132.3% in the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after acquiring an additional 41,335 shares during the last quarter. Finally, Americana Partners LLC acquired a new stake in shares of Rafael in the 2nd quarter valued at approximately $76,000. Institutional investors and hedge funds own 11.30% of the company’s stock.

Rafael Stock Performance

Shares of Rafael stock traded up $0.01 on Tuesday, reaching $1.21. 51,214 shares of the stock were exchanged, compared to its average volume of 75,084. The firm has a market cap of $62.38 million, a PE ratio of -1.42 and a beta of 0.68. The firm’s 50 day moving average is $1.25 and its 200-day moving average is $1.34. Rafael has a one year low of $1.12 and a one year high of $3.19.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Rafael in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.